Paper Details

  1. Home
  2. Paper Details

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).

Author: BokuNarikazu, HaraHiroki, HirataKenro, HironakaShuichi, KawakamiHisato, MasuishiToshiki, MatsumotoToshihiko, MuroKei, NagashimaKengo, TakahashiNaoki, YamazakiKentaro

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This article discusses a randomized phase II trial evaluating the efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) compared to FTD/TPI monotherapy in patients with advanced gastric cancer and esophagogastric junction adenocarcinoma.
Paper Details　
Original Abstract of the Article :
Trifluridine/tipiracil (FTD/TPI) prolongs survival in the third- or later-line treatment for advanced gastric cancer (GC), esophagogastric junction (EGJ) adenocarcinoma, and colorectal cancer. While single-arm phase II trials showed promising outcomes of FTD/TPI plus ramucirumab (RAM) as third- or l...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403909/

データ提供：米国国立医学図書館（NLM）

A New Treatment Combination for Advanced Gastric Cancer: A Promising Frontier

The field of [gastric cancer] treatment is constantly evolving, and this research explores a promising new combination therapy for [advanced gastric cancer] and [esophagogastric junction adenocarcinoma]. The authors are conducting a [randomized phase II trial] to compare the efficacy and safety of [trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM)] with [FTD/TPI monotherapy] as [third- or later-line treatments]. This study aims to provide valuable insights into the potential benefits of this novel combination therapy.

A New Oasis in the Treatment Landscape

The study is designed to provide a direct comparison of the two treatment regimens, allowing researchers to determine the true benefit of adding [ramucirumab] to the [FTD/TPI] regimen. This could lead to improved [tumor response] and [survival rates] for patients with [advanced gastric cancer]. The results will help to guide future clinical trials and potentially lead to the development of new treatment guidelines.

Navigating the Sands of Advanced Gastric Cancer

The findings of this study could have a significant impact on the treatment of [advanced gastric cancer]. It’s like finding a new oasis in a vast desert – a promising new treatment option that could significantly improve the lives of patients. By carefully analyzing the results of this trial, we can gain valuable insights into the potential benefits of this novel combination therapy, ultimately leading to improved outcomes for those battling this devastating disease.

Dr.Camel's Conclusion

This research is a promising step forward in the fight against [advanced gastric cancer]. By exploring the potential of new combination therapies, we can provide patients with more options and potentially improve their chances of survival. Like a caravan venturing into the desert, we need to continue to explore new routes and discover new solutions to effectively combat this challenging disease.

Date :
  1. Date Completed 2023-08-07
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

37543568

DOI: Digital Object Identifier

PMC10403909

Related Literature

Article Analysis
・Effects of trifluridine and tipiracil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.